New Clinical Trial Reporting Bill Risks Spooking Investors

Law360, New York (August 3, 2012, 8:54 PM EDT) -- A new bill aimed at broadening the amount of clinical trial data available on the government's public database would expose early data to drug and device sponsors' investors and competitors, potentially scaring off capital or revealing business strategies, experts say.

Led by Rep. Ed Markey, D-Mass., several Democrats introduced a bill Thursday that potentially would add reams of new data to the Clinicaltrials.gov database by expanding reporting requirements to Phase I trials and studies performed outside the U.S. that are used to support U.S. Food and...
To view the full article, register now.